Evaluation of an Eye Tracking Sensor to Detect Cannabis Impairment (NCT03994926) | Clinical Trial Compass
TerminatedEarly Phase 1
Evaluation of an Eye Tracking Sensor to Detect Cannabis Impairment
Stopped: COVID-19 Pandmic halted study
United States3 participantsStarted 2020-02-03
Plain-language summary
The purpose of this study is to determine if an eye tracking impairment sensor can detect cannabis-induced impairment after using cannabis.The overall objective is to correlate measures collected from the eye tracking sensor with measures related to cannabis impairment (e.g., plasma THC levels, self-reported cannabis subjective effects, cognitive effects).
Who can participate
Age range
18 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Willing to sign a confidentiality agreement stating the will not discuss study specifics, information or materials presented to them in the study with those not involved in the study;
. Currently living in Baltimore City or Baltimore County, MD, or Investigator discretion;
. Able to read, understand, and sign informed consent;
. 18-55 years old;
. Self-reports lifetime smoking of cannabis at least 10 times without any negative side effects;
. Self-reports past-year smoking of cannabis at least 1 time but no more than 2 days per week on average;
. Designation of Medically Healthy for Research by the Study Physician.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change from baseline in Pupil Dilation
Timeframe: Before and after smoking (up to 240 minutes)
2
Change from baseline in Gaze Nystagmus
Timeframe: Before and after smoking (up to 240 minutes)
3
Change from baseline in Lack of Convergence
Timeframe: Before and after smoking (up to 240 minutes)
. Agree to abstain from consuming alcohol for 10 hours and marijuana for 72 hour prior to the study visit
Exclusion criteria
. BAC \> 0.020% as measured by alcohol breathalyzer;
. Meets DSM-5 criteria for any current Axis I disorder other than mild or moderate Cannabis Use Disorder;
. Self-reported current desire to stop cannabis use, defined as 7 or greater on an 11-rung (scale of 0-10) on the Contemplation Ladder assessment;
. Self-reported current asthma, chronic obstructive pulmonary disease, hypertension, cardiovascular disease or any other medical illness that precludes participation based on the clinical judgment of the Study Physician and Investigative Team;
. Has difficulties with blood draws or poor venous access;
. History of blood donation in the past 30 days or receiving blood products within the past 2 months prior to any experimental visit;
. Investigator discretion due to self-reported use of medical cannabis or using cannabis for self-medication;
. Among females, current pregnancy or lactation or attempting to get pregnant, or at risk of becoming pregnant, as defined as being sexually active with a male partner and not willing to use a reliable form of contraception;